Observational study on early-onset colorectal cancer
Official title: Early-Onset Colorectal Cancer: An Observational Retrospective and Prospective Multicenter Study - (The HEBE Study)
Run by Niguarda Hospital · NCT06965335 · Data updated 2026-11-12
This study looks at young adults with colorectal cancer to learn more about the disease and find new treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Niguarda Hospital Academic / other |
| Locations | 1 site (Milan, Milano) |
| Status | Recruiting |
| Started | April 17, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | May 11, 2025 |
| Trial ID | NCT06965335 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 18-40 diagnosed with colorectal cancer or those over 60 diagnosed with standard-onset colorectal cancer.
✕Probably not a fit
Patients diagnosed with colorectal cancer outside the specified age ranges may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with colorectal cancer between the ages of 18 and 40. It aims to explore the biology of very early-onset colorectal cancer (vEO-CRC) through both retrospective and prospective data collection across multiple centers in Italy. The study will analyze clinicopathological features, survival data, and assess colibactin presence in tumor samples using advanced genomic techniques. Additionally, a subset of patients will undergo proteomic assessment to identify potential new therapeutic targets.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new therapeutic targets specifically for young colorectal cancer patients.
How similar studies have gone: Other studies have shown success in exploring the biology of colorectal cancer, but this specific focus on early-onset cases is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
1. Patients with diagnosis of colorectal cancer (vEO-CRC: 18-40 years of age), or SO-CRC diagnosed later than age 60; 2. Informed consent signature from alivepatient; 3. Availability of formalin-fixed paraffin embedded (FFPE) tumor samples (5 FFPE 4uM thick slides and 10 FFPE 10 uM thick slides) and/or fresh tumor tissue retrieved from a biopsy or surgical procedure performed as per clinical standard of care.
Where it's running
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, Milano, Italy Recruiting
Study contacts
- Study coordinator: Salvatore Siena, MD
- Email: salvatore.siena@ospedaleniguarda.it
- Phone: +39 02 6444
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prehabilitation before high-risk cancer surgery
This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.
-
Personal cancer risk testing using genetic, blood, and tumor monitoring
This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.
-
Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease
This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.
-
Colorectal Cancer Screening Outreach for Better Adherence
This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.
-
Blood-based delta-HLD methylation test for detecting colorectal cancer
This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.
-
MBRC-201 dose-finding and safety in advanced metastatic solid tumors
We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.